Cargando…

Once Daily High Dose Tigecycline Is Optimal: Tigecycline PK/PD Parameters Predict Clinical Effectiveness

Objective: The clinical effectiveness of tigecycline depends on appropriate use, and PK/PD (pharmacokinetic/pharmacodynamic) parameters related to dose and dosing interval. Methods: In our 600-bed university-affiliated teaching hospital, we conducted a tigecycline efficacy review over a three-month...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baron, Jeffrey, Cai, Shuntao, Klein, Natalie, Cunha, Burke A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2018
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867575/ https://www.ncbi.nlm.nih.gov/pubmed/29522431 http://dx.doi.org/10.3390/jcm7030049

Ejemplares similares

Once-daily tigecycline for outpatient parenteral antibiotic therapy: a single-centre observational study
por: Hughes, Stephen, et al.
Publicado: (2019)

High-dose tigecycline use in severe infections
por: De Pascale, G, et al.
Publicado: (2013)

A PK/PD study comparing twice-daily to once-daily dosing regimens of ertugliflozin in healthy subjects
por: Dawra, Vikas Kumar, et al.
Publicado: (2019)

Rational use of tigecycline and tigecycline blood concentration monitoring in patients with severe infection
por: Yu, Meiling, et al.
Publicado: (2023)

Tigecycline Susceptibility and the Role of Efflux Pumps in Tigecycline Resistance in KPC-Producing Klebsiella pneumoniae
por: He, Fang, et al.
Publicado: (2015)

Tigecycline Induced Hyperpigmentation of the Skin
por: Vandecasteele, S. J., et al.
Publicado: (2016)

Intra-abdominal infection after tumor surgery: tigecycline combined with β-lactam antibiotics versus tigecycline alone
por: Cai, Xinfeng, et al.
Publicado: (2023)

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013
por: Hoban, Daryl J, et al.
Publicado: (2015)

A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae
por: Sun, Lilan, et al.
Publicado: (2022)

Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients
por: Amann, Lisa F., et al.
Publicado: (2022)

Effects of tigecycline and doxycycline in porcine endotoxemia
por: Von Seth, M, et al.
Publicado: (2011)

Therapy of intracellular Staphylococcus aureus by tigecyclin
por: Kreis, Carolin A, et al.
Publicado: (2013)

The Transcriptomic Signature of Tigecycline in Acinetobacter baumannii
por: Li, Liping, et al.
Publicado: (2020)

Risk Factors for Tigecycline-Associated Hypofibrinogenemia
por: Liu, Jia, et al.
Publicado: (2021)

Resistance mechanisms of tigecycline in Acinetobacter baumannii
por: Sun, Chunli, et al.
Publicado: (2023)

Tigecycline Absorption Improved by Selected Excipients
por: Ziółkowski, Hubert, et al.
Publicado: (2023)

Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
por: Zhang, Lei, et al.
Publicado: (2023)

Acinetobacter Prosthetic Joint Infection Treated with Debridement and High-Dose Tigecycline
por: Vila, Andrea, et al.
Publicado: (2016)

Population Pharmacokinetics of High-Dose Tigecycline in Patients with Sepsis or Septic Shock
por: Borsuk-De Moor, Agnieszka, et al.
Publicado: (2018)

Pharmacokinetics of high-dose tigecycline in critically ill patients with severe infections
por: De Pascale, Gennaro, et al.
Publicado: (2020)

Hypofibrinogenemia induced by high-dose tigecycline—case report and review of literature
por: Fan, Qiaomei, et al.
Publicado: (2020)

Cutaneous Hyperpigmentation Secondary to High-Dose Tigecycline: A Case Report
por: Alsemari, Muhannad A., et al.
Publicado: (2020)

Emergence of tigecycline resistance in Escherichia coli co-producing MCR-1 and NDM-5 during tigecycline salvage treatment
por: Wang, Qian, et al.
Publicado: (2018)

Acute Generalized Exanthematous Pustulosis Associated with Tigecycline
por: Ozturk, Savas, et al.
Publicado: (2014)

Inhibition of Corneal Neovascularization by Topical and Subconjunctival Tigecycline
por: Goktas, Sertan, et al.
Publicado: (2014)

In Vitro Activity of Tigecycline Against Orientia tsutsugamushi
por: Lee, Sun-Myoung, et al.
Publicado: (2016)

Bacteriostatic and Bactericidal Effect of Tigecycline on Leptospira spp.
por: Bertelloni, Fabrizio, et al.
Publicado: (2020)

1456. Resistance Mechanisms of Tigecycline in Enterococcus faecalis
por: Bai, Bing, et al.
Publicado: (2020)

Genetic Determinants of Tigecycline Resistance in Mycobacteroides abscessus
por: Ng, Hien Fuh, et al.
Publicado: (2022)

Population Pharmacokinetics of Tigecycline: A Systematic Review
por: Zhou, Can-Can, et al.
Publicado: (2022)

Population pharmacokinetics of tigecycline in critically ill patients
por: Luo, Xiangru, et al.
Publicado: (2023)

Bloodstream infection with pandrug-resistant Alcaligenes faecalis treated with double-dose of tigecycline
por: Hasan, Md Jahidul, et al.
Publicado: (2019)

Tigecycline-Induced Severe Hypoglycemia in a Non-Diabetic Individual: A Case Report and Brief Review of Tigecycline-Induced Severe Hypoglycemia
por: Ray, Avik, et al.
Publicado: (2020)

The Synergistic Activity and Optimizing Doses of Tigecycline in Combination with Aminoglycosides against Clinical Carbapenem-Resistant Klebsiella pneumoniae Isolates
por: Nulsopapon, Parnrada, et al.
Publicado: (2021)

Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin
por: Estes, Kerry S, et al.
Publicado: (2010)

Pancreatitis in tigecycline Phase 3 and 4 clinical studies
por: McGovern, Paul C., et al.
Publicado: (2014)

Fitness of Escherichia coli mutants with reduced susceptibility to tigecycline
por: Linkevicius, Marius, et al.
Publicado: (2016)

Potential of Tetracycline Resistance Proteins To Evolve Tigecycline Resistance
por: Linkevicius, Marius, et al.
Publicado: (2016)

A Lesser Known Side Effect of Tigecycline: Hypofibrinogenemia
por: Yılmaz Duran, Fulya, et al.
Publicado: (2018)

Clinical Experience with Tigecycline in the Treatment of Prosthetic Joint Infections
por: Lastinger, Allison, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_hc4hkrsh93r4r7k0cprjt2o5r5